NASDAQ: FEEDEnvue Medical Inc Stock
$4.10+0.08 (+1.99%)
Updated Dec 12, 2025
FEED Price
$4.10
Fair Value Price
N/A
Market Cap
$4.46M
52 Week Low
$3.55
52 Week High
$162.50
P/E
-0.05x
P/B
0.11x
P/S
1.8x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.69M
Earnings
-$7.39M
Gross Margin
30%
Operating Margin
-258.99%
Profit Margin
-193.9%
Debt to Equity
0.28
Operating Cash Flow
-$7M
Beta
0.78
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
FEED Overview
NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices. The firm's products include UroShield and PainShield. It operates through the following geographical segments: United States, Europe, Australia, India, Israel, and Other. The company was founded by Harold Jacob and Jona Zumeris in September 2003 and is headquartered in Tyler, TX.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine FEED's potential to beat the market
- FEED doesn't meet the minimum data requirements for our proprietary Zen Ratings model. Learn more about Zen Ratings.
Zen Rating Component Grades
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Medical Device
Industry Rating
C
FEED
RankedUnranked of 105
RankedUnranked of 105
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $27.82 | A | |
| $11.71 | A | |
| $7.55 | A |
Be the first to know about important FEED news, forecast changes, insider trades & much more!
FEED News
Overview
Due Diligence Score
–
Industry Average (27)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how FEED scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
FEED is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
FEED is good value based on its book value relative to its share price (0.11x), compared to the US Medical Devices industry average (3.88x)
P/B vs Industry Valuation
FEED is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more FEED due diligence checks available for Premium users.
Valuation
FEED price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-0.05x
Industry
24.46x
Market
45x
FEED price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.11x
Industry
3.88x
FEED is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
FEED's financial health
Profit margin
Revenue
$722.0k
Net Income
$510.0k
Profit Margin
-108%
FEED's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
FEED's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$54.4M
Liabilities
$11.9M
Debt to equity
0.28
FEED's short-term liabilities ($11.64M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
FEED's short-term assets ($10.02M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
FEED's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
FEED's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$2.0M
Investing
-$28.0k
Financing
$4.9M
FEED's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
FEED vs Medical Device Stocks
Envue Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.